Detailed price information for Context Therapeutics Inc (CNTX-Q) from The Globe and Mail including charting and trades.
BOSTON, Oct. 14, 2026 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced it granted stock options to a new employee under the Company’s 2025 Inducement Plan and as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement grant consists of non-qualified stock options to purch
Compass Therapeutics (CMPX) stock slides as Wedbush downgrades the company on FDA call for a new study for lead asset tovecimig. Read more here.
Several analysts slashed their price targets on Compass Therapeutics after the FDA requested an additional trial for its cancer drug.
Analysts downgraded Accelerant, Autoliv, Compass Therapeutics, Wave Life Sciences and PG&E; price targets for CMPX and PCG were cut.
Compass Therapeutics (CMPX) has an average rating of buy and mean price target of $6.75, according t
Tipranks Press Release.
Detailed price information for Compass Therapeutics Inc (CMPX-Q) from The Globe and Mail including charting and trades.
Tipranks Press Release.
Compass Therapeutics, Inc. (NASDAQ:CMPX) shares are trading lower on Tuesday as the FDA feedback raises new questions about the timing and requirements for its tovecimig program. The move is coming even as S&P 500 futures are up 0.1%, pointing to stock-specific pressure rather than a broad risk-off tape. Read Also: Compass Therapeutics' Bile Duct Cancer Drug Seen As New Standard Of Care CMPX Stock Drops After FDA Feedback On Tovecimig BLA Path Compass said the FDA recommended the company run a t
Compass Therapeutics shares plunge after FDA seeks a survival-benefit trial before tovecimig’s FDA marketing application.
Gainers Jaguar Health (NASDAQ:JAGX) stock increased by 304.5% to $10.8 during Tuesday's regular session. The company's market cap stands at $1.1 million. Greenland Mines (NASDAQ:GRML) shares moved upwards by
The FDA recommended that Compass conduct a trial to demonstrate a survival benefit prior to submitting a BLA for tovecimig.Compass does not believe that a new trial is warranted prior to submitting a BLA based on the data from the Phase 2/3 COMPANION-002 study and the urgent unmet medical need for patients with BTC.Compass intends to further engage with the FDA as we continue to prepare a BLA submission for tovecimig. Compass remains confident in tovecimig based on the positive results from COMP
This is the newest page. Registered accounts read further back.